Attached files
| file | filename |
|---|---|
| 8-K - ZIOPHARM ONCOLOGY INC | v209713_8-k.htm |
Exhibit 99.1
ZIOPHARM
ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
NEW YORK, NY – February 2,
2011 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced that it is
offering to sell 9,600,000 shares of its common stock pursuant to an effective
shelf registration statement in an underwritten public offering. Barclays
Capital Inc. is acting as sole book-running manager in this offering and
ZIOPHARM has granted the underwriter a 30 day option to purchase up to 1,440,000
additional shares. The public offering is subject to market conditions, and
there can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.
The
securities described above are being offered by ZIOPHARM pursuant to a shelf
registration statement previously filed with and declared effective by the
Securities and Exchange Commission (the “SEC”) on May 13, 2010. A preliminary
prospectus supplement related to the offering has been filed with the SEC and is
available on the SEC’s web site at http://www.sec.gov. Copies of the preliminary
prospectus supplement relating to these securities may be obtained from Barclays
Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone:
888-603-5847).
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of, the shares in any state or other
jurisdiction which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or
other jurisdiction.
About
ZIOPHARM Oncology, Inc.
ZIOPHARM
Oncology is a biopharmaceutical company engaged in the development and
commercialization of a diverse portfolio of cancer therapeutics. The Company is
currently focused on several clinical programs. Palifosfamide (ZymafosTM or
ZIO-201) references a novel composition (tris formulation) that is the
functional active metabolite of ifosfamide, a standard of care for treating
sarcoma, and other cancers. Darinaparsin (ZinaparTM or
ZIO-101) is a novel organic arsenic being developed for the treatment of various
hematologic and solid cancers. Indibulin (ZybulinTM or
ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and
cancer cell migration. ZIOPHARM is also pursuing the development of novel
DNA-based biotherapeutics in the field of cancer pursuant to a partnering
arrangement with Intrexon Corporation. The partnership includes a clinical-stage
product candidates in a Phase Ib study a second product candidate that is the
basis of an Investigational New Drug application that ZIOPHARM expects to submit
during the first half of 2011.
ZIOPHARM’s
operations are located in Boston, MA with an executive office in New
York.
Forward-Looking
Safe Harbor Statement
This
press release contains forward-looking statements, including statements related
to ZIOPHARM Oncology's public offering of common stock and the completion of the
offering that involve risks and uncertainties. These forward-looking statements
are based upon ZIOPHARM Oncology's current expectations. Actual results and the
timing of events could differ materially from those anticipated in such
forward-looking statements as a result of risks and uncertainties, which
include, without limitation, risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions related to the
proposed offering and other risks detailed in ZIOPHARM Oncology's filings with
the Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of
this press release. All forward-looking statements are qualified in their
entirety by this cautionary statement, and ZIOPHARM Oncology undertakes no
obligation to revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
# # #
Contact:
Tyler
Cook
ZIOPHARM
Oncology, Inc.
617-259-1982
tcook@ziopharm.com